参考资料 [1]Jonathan Spicer. Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo)vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. https://meetings.asco.org/2024-asco-annual-meeting/15...
参考资料 [1]Jonathan Spicer. Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. https://meetings.asco.org/2024-asco-annual-meeting/15777?presentation=232352%23232352...
[1]Jonathan Spicer. Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. https://meetings.asco.org/2024-asco-annual-meeting/15777?presentation=232352%23232352 免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。
CheckMate 816对可切除NSCLC4患者的新辅助nivolumab联合化疗与化疗4年更新.pptx,Neoadjuvant nivolumab plus chemotherapy vs chemotherapy in patients with resectable NSCLC: 4-year update from CheckMate 816Content of this presentation is the property of the auth
纳武利尤单抗联合含铂双药化疗 vs 化疗,对可切除NSCLC进行新辅助治疗:来自 CheckMate 816 的健康相关生活质量 (HRQoL) 结局 原标题:Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non...
9016 Background: 1L NIVO + IPI was shown to provide durable long-term overall survival (OS) benefit vs chemo regardless of tumor programmed death ligand 1 (PD-L1) expression in patients (pts) with advanced NSCLC in CheckMate 227 Part 1 (NCT02477826); 3-year OS rates were 33% vs 22% ...
In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) or less than 1% (prespecified descriptive analysis). We report results with minimum 4 years' ...
To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC). Methods Patients with aRCC with ...
在今年的美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO GI)上,百时美施贵宝公布了「YO 双免」(伊匹木单抗和纳武利尤单抗)治疗 MSI-H/dMMR 结直肠癌的 III 期临床研究 CheckMate-8HW 的最新结果:「 YO 双免 」方案与纳武利尤单抗单...
PLoS ONE 8(2): e56666 (Year: 2013). NCT02060188. Bristol-Myers Squibb. A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (CheckMate 142). Available from: https://clinicaltrials.gov/ct2/show/NCT 02060188. NLM identifier. NCT ...